

# Lung Cancer Survey (Pemetrexed use analysis)

## A. Oncologist Details -

### Qualification:

- Place of working - Govt. Hospital / Teaching Hospital/ Research Centre / Private Hospital/ Clinic / Other
  
- Primary area of practice - Medical Oncology / Radiation Oncology / Surgical Oncology / pulmonology / Physician

## B. About Patients Load -

- New lung cancer per month
- New NSCLC Patients per month
- Chemo naive NSCLC per month

## C. Diagnostic Method -

How you diagnose your lung cancer patients -

- |   |   |
|---|---|
| • Bronchoscopy & biopsy -               | % |
| • CT guided FNAC of lung SOL            | % |
| • CT guided true cut biopsy of lung SOL | % |
| • Other site biopsy                     | % |
| • Other site FNAC                       | % |

---

100%

## D. No. of your new patients / month who are in stage IIIB or IV -

## E. Treatment Choice (In NSCLC) -

1. Ist Line patients: Do you consider non Squamous vs. Squamous histology Important before considering treatment YES / NO

2. (i) What is first choice of treatment in Squamous cell HP:-

Gemcitabine / Paclitaxel / Docitaxel / Vinorelbine/ Pemetrexed/ Etoposide/  
or TKI (Gefotinib/Erlotinib)

- (ii) What is first choice of treatment in non squamous cell HP

Gemcitabine / Paclitaxl / Docitaxel / Vinorelbine / Pemetrexed / Etoposide  
/ or TKI (Gefotinib/Erlotinib)

(iii) How many new patients you enroll for pemetrexed based protocol in chemo naive patients / month

0-5       5-10       11-15       >15

(IV) How many relapse patients you enroll for pemetrexed based protocol / month

0-5       5-10       11-15       >15

(V) Do you agree that maintenance pemetrexed is useful YES / NO

(VI) (If Yes) – How many patients you have on

maintenance Protocol / Month       0-5       >5

#### **F. About Pemetrexed in NSCLC -**

(I) Do you agree that Pemetrexed/ Cisplatin Combination is better than other slandered doublet in clinical practice YES / NO

(ii) Do you get proper information from pharma representatives about pemetrexed YES / NO

(iii) Role of pemetrexed will  
Increase / Decrease / Remain Same / Not Sure

(IV) What is main difficulty in using pemetrexed (You can tick more than one choice)

- Cost
- Premedication (Vit. B12), waiting period of 7 days
- Lack of additional benefit over standard doublet
- Side effects profile
- Others (In your opinion)

G. Are you interested in post marketing surveillance (Phase IV) clinical trial of pemetrexed based protocol YES / NO

H. Your Comment /Suggestion to increase the use of Pemetrexed in NSCLC

Sign. / Name (Optional)